The impact of the Falsified Medicines Directive in the dispensing operations of an Austrian hospital pharmacy

Autor: Koshkouei Mj, Jeske M, Brindley Da, Pinto de Cn, Zeiler M

Publikováno v: Journal of Hospital and Medical Management. 3(1)

The Falsified Medicines Directive (FMD) and the Delegated Regulation (DR) will need to be implemented in the next couple of years to ensure compliance of dispensing operations in the secondary environment. This study was developed in an Austrian hosp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0a4b162cd6d6256a2ade1cbcc34750f
http://ora.ox.ac.uk/objects/uuid:

Optimising the quality and effectiveness of risk : benefit appraisal methodologies utilised in randomised control trials

Autor: Brindley, David

Externí odkaz: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.658530

Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model.

Autor: Halioua-Haubold CL; Department of Paediatrics, University of Oxford, Oxford, UK., Jolly JK; Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, UK.; Moorfields Eye Hospital, London, UK.; Oxford University Hospitals National Health Service Foundation Trust, Oxford, UK., Smith JA; Nuffield Departments of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.; Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK., Pinedo-Villanueva R; Nuffield Departments of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK. rafael.pinedo@ndorms.ox.ac.uk., Brindley DA; Department of Paediatrics, University of Oxford, Oxford, UK.; Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK., MacLaren RE; Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, UK.; Moorfields Eye Hospital, London, UK.; Oxford University Hospitals National Health Service Foundation Trust, Oxford, UK.

Publikováno v: Eye (London, England) [Eye (Lond)] 2019 Aug; Vol. 33 (8), pp. 1215-1223. Date of Electronic Publication: 2019 Jul 17.

Bioprocess decision support tool for scalable manufacture of extracellular vesicles.

Autor: Ng KS; Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts.; Division of Engineering in Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.; Harvard Stem Cell Institute, Cambridge, Massachusetts.; RoosterBio, Frederick, Maryland., Smith JA; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.; The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK., McAteer MP; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts., Mead BE; Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts.; Division of Engineering in Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.; Harvard Stem Cell Institute, Cambridge, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts., Ware J; The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK., Jackson FO; The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK., Carter A; Department of Paediatrics, University of Oxford, Oxford, UK., Ferreira L; University of Coimbra, Center for Neuroscience and Cell Biology, Portugal., Bure K; The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK., Rowley JA; RoosterBio, Frederick, Maryland., Reeve B; Harvard Stem Cell Institute, Cambridge, Massachusetts., Brindley DA; Harvard Stem Cell Institute, Cambridge, Massachusetts.; The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK.; Department of Paediatrics, University of Oxford, Oxford, UK.; Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, UK.; UCSF-Stanford Center of Excellence in Regulatory Science and Innovation, San Francisco, California., Karp JM; Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts.; Division of Engineering in Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.; Harvard Stem Cell Institute, Cambridge, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

Publikováno v: Biotechnology and bioengineering [Biotechnol Bioeng] 2019 Feb; Vol. 116 (2), pp. 307-319. Date of Electronic Publication: 2018 Nov 08.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Autor: Carter AR; 1 Department of Paediatrics, Healthcare Translation Research Group, University of Oxford , Oxford, United Kingdom ., Meinert E; 1 Department of Paediatrics, Healthcare Translation Research Group, University of Oxford , Oxford, United Kingdom .; 2 Department of Primary Care and Public Health, Imperial College London , London, United Kingdom ., Brindley DA; 1 Department of Paediatrics, Healthcare Translation Research Group, University of Oxford , Oxford, United Kingdom .

Publikováno v: Rejuvenation research [Rejuvenation Res] 2018 Aug; Vol. 21 (4), pp. 291-293.